Axovant Gene Therapies Ltd. (AXGT)
| Market Cap | 88.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.17M |
| Shares Out | 43.29M |
| EPS (ttm) | -1.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Nov 12, 2021 |
| Last Price | $2.10 |
| Previous Close | $2.10 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 2.07 - 2.17 |
| Day's Volume | 0 |
| 52-Week Range | 1.41 - 6.12 |
News
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. ("Axovant" or the "Company") (NASDAQ: AXGT). Such investors ...
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Dr...
NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtu...
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...
The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.
Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020 Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020
Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...
• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline ...
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will pre...
These underappreciated biotechnology start-ups could turn heads one day -- but not yet.
AXGT has promising gene therapy results in Parkinson's Disease.
Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
NEW YORK and BASEL, Switzerland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...
- Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists
NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for ...
Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD
NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...
Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEW YORK and BASEL, Switzerland, June 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...
- Six-month data from low-dose cohort expected in Q4 2020 - IND amended to include Type I (infantile onset) patients and to evaluate a higher dose - Expect to initiate high-dose cohort ...
Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for May 5th
Company’s balance sheet is now free of debt Company’s balance sheet is now free of debt
NEW YORK and BASEL, Switzerland, April 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, toda...
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten...
NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 1...
NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offerin...
Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019
NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided f...
NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which ...
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced ...
Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.
BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag M...
Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.
Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird.
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological dis...
Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.
As of late, it has definitely been a great time to be an investor Axovant Sciences.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.
About AXGT
Axovant Gene Therapies, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Scien... [Read more...]
| Industry Biotechnology | Founded 2014 |
| CEO Pavan Cheruvu | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol AXGT |